Immunization

Novavax announced the development of a protein-based monovalent XBB COVID-19 vaccine with the intention of it being manufactured and available for the fall vaccination campaign.

A single dose of Arexvy was found effective preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older across 2 full RSV seasons.

Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.

Adult and maternal RSV vaccines reveal positive findings.

A broader understanding of vaccine hesitancy and barriers has helped to enhance acceptance of vaccination services through educational outreach.

Study investigators said that understanding how the human immune response relates to respiratory syncytial virus infection has been a major obstacle for vaccine development.

Pharmacists who immunize must ensure their knowledge about routine vaccinations for adults and children is up-to-date by reviewing the changes to the immunization schedule each year.

Ambulatory care pharmacy residents play a major role in increasing both patient awareness about recommended vaccination and vaccination rates.

Myths, fears, distrust, and misinformation on immunizations can keep patients from benefiting from their protective effects.

Treatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.

Navigating the Transition to Year-Round Immunization

Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

As the summer months approach, pharmacists can offer many services to ensure patients remain safe and healthy during their travels.

Women with recurrent urinary tract infections (UTIs) are often on and off antibiotics for years, and even decades, as the only treatment available in health systems for treating UTIs.

Reporting vaccination data to Immunization Information Systems databases can support public health surveillance activities.

The FDA’s final decision is expected by a Prescription Drug User Fee Act goal date in August 2023.

From 2017 to 2021, Australia did not experience a large increase in infections of serotype 19A across all ethnic and age groups, unlike New Zealand.

Findings suggest that mice derived from and breastfed by immunized mothers were capable of producing anti- pneumococcal surface protein A (PspA) specific antibodies, despite having no direct exposure to PspA.

Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.

PCV10 protection is likely to have reduced the incidence of pneumococcal disease among all ages by between 48% and 66%.

Investigators of the phase 2 study also found a comparable reactogenicity to the individual influenza and COVID-19 vaccines from Novavax or authorized vaccine comparators.

The 2022-2023 COVID-19 season did not have a significant surge of COVID-19 like it did early on in the COVID-19 pandemic.

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

The study shed light on the importance of the source of vaccine information and other factors that prevent lifesaving vaccination.

It is possible that the pandemic had a positive impact on influenza vaccination rates.

Study sheds light on the importance of the source of vaccine information and other factors that prevent lifesaving influenza or pneumococcal vaccination.

Misinformation on YouTube promotes women wiping front to back as a non-evidence-based hygiene practice to prevent urinary tract infection.

Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Neutralizing monoclonal antibody therapies found to improve outcomes for unvaccinated and nonhospital patients at high risk of poor outcome for SARS-CoV-2.

The BCG vaccine was more likely to cause symptomatic or severe COVID-19 in patients that had a preexisting condition, such as heart disease, by 6 months.